Consequences of delayed treatment effects on analysis of time-to-event endpoints

Drug Information Journal

Volumn 41, Issue 4, 2007, Pages 535-539

  Fine, Gil D ^a  

^a SuperGen Inc   (United States)

Author keywords

Log rank; Pancreatic cancer; Power; Survival analysis; Weighted test

Indexed keywords

ARTICLE; CLINICAL RESEARCH; HYPOTHESIS; LOG RANK TEST; MATHEMATICAL ANALYSIS; METHODOLOGY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STANDARD;

EID: 34447287767     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150704100412     Document Type: Article

References (6)

1. Jacobs AD. A randomized phase III study of rubitecan (ORA) versus best choice (BC) in 409 patients with refractory pancreatic cancer, report from a North-American multicenter study. Presented at: Annual Meeting of the American Society of Clinical Oncology; 2004; New Orleans, LA.
2. Fleming TR, Arrington DP. Counting Processes and Survival Analysis. New York: John Wiley; 1991.
3. SAS Institute Inc. SAS/STAT® 9.1 User's Guide. Cary, NC: SAS Institute; 2004.
4. Cantor AB. SAS® Survival Analysis Techniques for Medical Research. 2nd ed. Cary, NC: SAS Institute; 2003.
5. Lakatos E. Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics. 1988;44:229-241.
6. Harrington DP, Fleming TR. A class of rank test procedures for censored survival data. Biometrika. 1982;69:553-566.